Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (PACB) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
pacb · stock forecast · 18 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 18 Wall Street analysts in the past 3 months
Buy
18 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$1.00
Consensus
$1.00
-27.5% upside
Low
$1.00
Median: $1 · Last Close: $1.38
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.45 | ↑ 5.00% |
1-day model range: $1.43–$1.46. Peak: $1.46 (+5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -50.0% |
| 2028 | $1 | -63.7% |
| 2029 | $0 | -69.2% |
| 2030 | $0 | -71.8% |
| 2031 | — | -73.1% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PACB · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-11 | Barclays | Maintains | Underweight→Underweight |
| 2026-04-14 | Barclays | Maintains | Underweight→Underweight |
| 2026-03-06 | Barclays | Downgrade ↓ | Equal Weight→Underweight |
| 2025-12-15 | Barclays | Maintains | Equal Weight→Equal Weight |
| 2025-11-11 | Piper Sandler | Maintains | Neutral→Neutral |
| 2025-11-10 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2025-08-11 | Piper Sandler | Maintains | Neutral→Neutral |
| 2025-06-25 | Barclays | Maintains | Equal Weight→Equal Weight |
| 2025-05-15 | Piper Sandler | Maintains | Neutral→Neutral |
| 2025-05-15 | Stephens & Co. | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Pacific Biosciences of California, Inc. (PACB) stock. Of the recent 91 rating actions, 11 were upgrades and 13 were downgrades. 18 analysts currently cover PACB.
Analyst Recommendation Trends
PACB analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$168M
↓ 24.3% YoY
Revenue Next Year
$194M
↑ 15.5% YoY
EPS This Year
$-0.41
EPS Next Year
$-0.47
↑ 14.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast PACB EPS of $-0.41 for the current fiscal year, based on estimates from 3 analysts. The PACB revenue forecast is $168M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PACB stock forecast is supported by two independent data sources: analyst consensus ratings from 18 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PACB price target is $1.00 (-27.5% upside), with an analyst consensus of Buy.
The PACB short-term stock prediction for tomorrow is $1.45 (+5.00%). The PACB stock price prediction for 2027 estimates an average of $1. The PACB stock prediction for 2030 projects a range of $0–$0.
Pacific Biosciences of California, Inc. trades on NASDAQ under the ticker PACB. The PACB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
PACB forecast · 8 questionsAccording to 18 Wall Street analysts, the average 12-month PACB price target is $1.00, with a high forecast of $1.00 and a low of $1.00. The median price target is shown in the chart above when available. This implies -27.5% potential upside from the current price of $1.38.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.